Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance
Published . Updated .
Key takeaways
- Jazz Pharmaceuticals (NASDAQ:JAZZ) is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event.
- Exposed: JAZZ, LLY, JNJ, PFE, MRK
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
Jazz Pharmaceuticals (NASDAQ:JAZZ) is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event. Gala pointed to third-quarter revenue of $1.24
Directly affected
- JAZZ Jazz Pharmaceuticals+10.1% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+25.0% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| JAZZ | +4.14% | +7.59% | base | after close | after close | after close | after close |
| XLV | +5.96% | +2.17% | base | after close | after close | after close | after close |
| XBI | +4.00% | +3.40% | base | after close | after close | after close | after close |
| LLY | +6.37% | +2.56% | base | after close | after close | after close | after close |
| JNJ | +4.35% | +0.70% | base | after close | after close | after close | after close |
| PFE | +5.31% | +2.32% | base | after close | after close | after close | after close |
| MRK | +8.11% | +3.06% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance Yahoo Finance
Source: Yahoo Finance
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| JAZZ | three days earlier | +7.59% | final price |
| JAZZ | five days earlier | +4.14% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +0.70% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +4.35% | final price |
| Eli Lilly (LLY) | three days earlier | +2.56% | final price |
| Eli Lilly (LLY) | five days earlier | +6.37% | final price |
| Merck (MRK) | three days earlier | +3.06% | final price |
| Merck (MRK) | five days earlier | +8.11% | final price |
| Pfizer (PFE) | three days earlier | +2.32% | final price |
| Pfizer (PFE) | five days earlier | +5.31% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.40% | final price |
| Spdr Series Trust (XBI) | five days earlier | +4.00% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +2.17% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +5.96% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Michael Rulli sold Eli Lilly (LLY), worth $1,001 - $15,000 on 4 Nov 2026. That is 17 days before publication. Filed 18 Nov 2026. View the filing.
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 18 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 32 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 27 Oct 2026. That is 25 days before publication. Filed 19 Nov 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 45 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 52 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 78 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $15,001 - $50,000 on 2 Sep 2026. That is 80 days before publication. Filed 19 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 58 days before publication. Filed 19 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- MRK Merck
In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
Select Sector Spdr Tr (XLV) and the energy link
The 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance” names Select Sector Spdr Tr (XLV) because of Energy.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Dates in the story, and the Select Sector Spdr Tr (XLV) price range
LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance” scores 46 out of 100. The score uses 1 source, and 6 linked companies.